We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

SCRI Tissue Testing Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00965861
Recruitment Status : Terminated (Replaced by a study with a similar design.)
First Posted : August 26, 2009
Last Update Posted : August 28, 2013
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Condition or disease Intervention/treatment
Melanoma Myelodysplastic Syndrome Multiple Myeloma Lymphoma Other: Tissue Registry Study

Detailed Description:

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).


Study Design

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Official Title: SCRI Tissue Testing Registry
Study Start Date : May 2010
Primary Completion Date : February 2013
Study Completion Date : February 2013


Groups and Cohorts

Group/Cohort Intervention/treatment
1
The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
Other: Tissue Registry Study
If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.


Outcome Measures

Primary Outcome Measures :
  1. To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing. [ Time Frame: 120 months ]
  2. To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases [ Time Frame: 120 months ]

Biospecimen Retention:   Samples With DNA
Potential retention of tissue blocks for future study.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
Criteria

Inclusion Criteria:

  • Patients must be >= 18 years of age.
  • Patients must be able to provide written informed consent.

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00965861


Locations
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
Sponsors and Collaborators
SCRI Development Innovations, LLC
Investigators
Study Chair: Howard Burris, M.D. SCRI Development Innovations, LLC
More Information

Responsible Party: SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier: NCT00965861     History of Changes
Other Study ID Numbers: SCRI MISC 39
First Posted: August 26, 2009    Key Record Dates
Last Update Posted: August 28, 2013
Last Verified: August 2013

Keywords provided by SCRI Development Innovations, LLC:
Tissue Registry
Tissue Collection
Unknown Primary
Breast
Lung
Gastrointestinal
Bone Marrow Transplant
Chronic Lymphocytic Leukemia
Central Nervous System
Head and Neck
Melanoma
Myelodysplastic syndrome
Multiple Myeloma
Lymphoma
Gynecologic
Genitourinary
Refractory Malignancy

Additional relevant MeSH terms:
Melanoma
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Preleukemia
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Precancerous Conditions